Alembic receives USFDA final approval for Ticagrelor Tablets, 90 mg and tentative approval for Ticagrelor Tablets, 60 mg
Ticagrelor tablets are indicated for to reduce the risk of cardiovascular death and myocardial infarction,
Ticagrelor tablets are indicated for to reduce the risk of cardiovascular death and myocardial infarction,
Niacin is indicated to reduce elevated total cholesterol, LDL cholesterol, apolipoprotein B and triglycerides (TG)
Phesgo label expansion delivers on patients’ preference for at-home administration and is an important step in freeing up cancer care capacity in clinical settings
Alembic Pharmaceuticals commissions new facility at Pithampur
This Product is indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension
Vimta Labs has reported total income of Rs. 96.08 crores during the period ended March 31, 2025
Celecoxib Capsules approval complements Strides’ existing products to serve a broader patient base
ekincare has raised a total funding of $22M since 2015 till date
The company has posted net profit of Rs. 406.7 crores for the Financial Year ended March 31, 2025
Investment demonstrates confidence in America’s commitment to science and innovation
Subscribe To Our Newsletter & Stay Updated